Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda to Establish Global Customer Market Business Insights Department
December 26, 2012
- Takeda Voluntarily Recalls Ethical Version of Alinamin-F5 Injection
December 26, 2012
- Immunotherapeutic Cancer Drug Fails to Meet Primary Endpoint in PIII Study: Merck Serono
December 25, 2012
- Mortality Rate of Patients After Major Bleeds Significantly Lower with Dabigatran: BI
December 25, 2012
- Safety of Xarelto Found to Be “Consistent with Clinical Trial Data” in EPPV: Bayer Yakuhin
December 25, 2012
- Generic-only Companies Which Rely on Wholesales Worried About Decline in Their Relative Position with Wholesalers
December 25, 2012
- Increasing Competition in AD Drug Market; Sales of Over 240 Billion Yen Predicted by 2020
December 25, 2012
- Novartis Files for Approval of Combination Drug of Rasilez, CCB
December 21, 2012
- Nexium Dominates No.1, 2 Ranking in HP Market for 3rd Consecutive Month: Rep Track Survey
December 21, 2012
- Bayer Files for Approval of Radioactive Anticancer Agent in US and Europe
December 20, 2012
- Dolutegravir Filed for Approval in Europe, the US and Canada: Shionogi
December 20, 2012
- Sanofi’s JAK2 Inhibitor Improves Symptoms in Patients with MF in PII Trial
December 20, 2012
- Carsten Brunn to Take Over as President of Bayer Yakuhin in March 2013
December 20, 2012
- Eisai Transfers US Rights for Brain Tumor Treatment to Arbor Pharm
December 19, 2012
- Crestor Patent Upheld by US Court of Appeals for the Federal Circuit: Shionogi
December 19, 2012
- Takeda to Sell URL Pharma’s Generic Drug Business to Caraco
December 19, 2012
- Elmed Eisai, Kobayashi Kako Allegra Generics Not Launched on December 14
December 18, 2012
- Takeda Faces Generic Entry for Candesartan in US
December 18, 2012
- Eisai to Form Alliance with University College London for Drug Discovery Research
December 18, 2012
- Chugai to Adopt IFRS from FY2013
December 18, 2012
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…